Zantac 75 Pediatric Exclusivity Opposed In Novopharm Petition
This article was originally published in The Tan Sheet
Executive Summary
Awarding six months of pediatric exclusivity to Glaxo's Zantac 75 would be "contrary to the public interest because it would frustrate the intent of Congress," Novopharm argues in a Nov. 19 citizen petition to FDA.